FerroKin projects once-daily oral tablet could reach the market by 2016.
Almirall gains MS drug license in Mexico and will pay GW less for Sativex supply.
Preclinical-stage firm is developing drugs that modulate cannabinoid pathways.
Model will enable study of autoimmune disorders and facilitate development of personalized therapies.
Marina is entitled to $14 million in total fees per gene target plus royalties.
ZsBio was established in 1993 and is based in Beijing.
Firms cite differing priorities that favor independence.
Talactoferrin is in Phase III studies against non-small-cell lung cancer.
Firm's adjuvanting technology will be coupled with Cornell's vaccine.
Monitoring and control methodology will be developed for EMD's Mobius CellReady bioreactor.
View more news updated daily on the GEN website.
|
